Posted by Michael Wonder on 24 Sep 2024
Merck receives positive EU CHMP opinions for Keytruda (pembrolizumab) regimens as treatment for patients with two types of gynaecologic cancers
20 September 2024 - Positive opinion granted for Keytruda plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, based on the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868.
Merck today announced that the EMA’s CHMP adopted positive opinions recommending approval of KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, for two indications in gynaecologic cancers.
